efficacy and gene expression results from eribulin solti1007 neoadjuvant study
Published 8 years ago • 97 plays • Length 5:49Download video MP4
Download video MP3
Similar videos
-
3:26
pd-1 therapy with eribulin for triple negative mbc
-
3:53
bylieve study results: alpelisib and endocrine therapy in patients with pik3ca-mutated/hr /her2-...
-
8:31
#esmo21 expert video report on her2-positive early breast cancer
-
2:32
neoadjuvant biomarker analysis of neorhea: palbociclib in er /her2- bc
-
1:19
gene expression assays to identify patients with breast cancer for neoadjuvant treatment
-
2:20
dr. llombart-cussac on eribulin in her2-negative metastatic breast cancer
-
6:34
neoadjuvant therapy with neratinib plus trastuzumab in locally advanced her2-positive breast cancer
-
5:00
adjuvant endocrine therapy used to treat er her2- breast cancer
-
5:52
oestrogen deprivation inffective with chemo for hr/her positive breast cancer
-
8:52
real-world outcomes of her2 and tnbc patients recieving neoadjuvant chemotherapy
-
1:59
effectiveness of icis in the neoadjuvant and post-neoadjuvant breast cancer setting
-
2:09
hrd, rb-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in hr /her2- early bc
-
1:29
the genetics of breast cancer complete response
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
0:38
rxponder: 21-gene assay informs chemotherapy benefit in hr node-positive breast cancer
-
0:53
eleanor: real-world study of extended adjuvant neratinib in her2 /hr early breast cancer
-
0:54
treatment de-escalation in premenopausal patients with hr /her2- breast cancer and micro-metastasis
-
1:22
analyzing predictors of response to neoadjuvant chemotherapy in breast cancer
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?